CKD Bio is targeting overseas markets for botulinum toxin drugs under development. CKD Bio announced on the 19th that it has signed a supply contract with Cutia Therapeutics for Tyemvers, a botulinum toxin. The size of the contract is 8.3 billion won, which supplies the product to China, Hong Kong, Macau, and Taiwan for 15 years after licensing Chinese products.

The step-by-step milestone is a condition that receives $2.5 million when applying for a clinical trial plan in China and $1 million and $1.5 million when approving product licenses in Korea and China, respectively. Tyemvers is the product name of a botulinum toxin drug under development by CKD Bio. This contract is the first overseas expansion sig